iBio, Inc. (NYSEMKT:IBIO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
At the 2016 Annual Meeting of Stockholders of iBio, Inc. (the
Company) held on May 4, 2017, Proposals 1, 2 and 3 were each
approved by the Companys stockholders. The proposals are
described in detail in the definitive proxy statement filed by
the Company with the Securities and Exchange Commission on April
6, 2017. The final voting results of the 2016 Annual Meeting are
set forth below.
Proposal 1 – Election of Directors – The Companys stockholders
elected Glenn Chang and Philip K Russell, M.D. to serve as Class
II directors of the Company for a three-year term expiring in
2019. The voting results for each of these individuals were as
follows:
| Director | Votes For | Votes Withheld | Broker Non-Votes |
| Glenn Chang | 50,559,811 | 698,846 | 24,777,411 |
| Philip K Russell, M.D. | 50,591,769 | 666,888 | 24,777,411 |
Proposal 2 – Ratification of the selection of the Companys
independent registered public accounting firm – The Companys
stockholders ratified the selection of CohnReznick LLP as the
Companys independent registered public accounting firm for the
current fiscal year ending June 30, 2017. The voting results were
73,312,244 shares FOR, 1,528,400 shares AGAINST, and 1,195,424
abstentions.
Proposal 3 Say on pay proposal – The Companys stockholders
approved, on an advisory basis, the compensation of its named
executive officers. The voting results were 49,873,949 shares
FOR, 1,269,760 shares AGAINST, 114,948 abstentions and 24,777,411
broker non-votes.
About iBio, Inc. (NYSEMKT:IBIO)
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company’s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company’s technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma. iBio, Inc. (NYSEMKT:IBIO) Recent Trading Information
iBio, Inc. (NYSEMKT:IBIO) closed its last trading session down -0.020 at 0.390 with 57,236 shares trading hands.
